Next Article in Journal
Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma
Next Article in Special Issue
Intra-Tumoral Secondary Follicle-like Tertiary Lymphoid Structures Are Associated with a Superior Prognosis of Overall Survival of Perihilar Cholangiocarcinoma
Previous Article in Journal
Targeted Depletion of Hyaluronic Acid Mitigates Murine Breast Cancer Growth
Previous Article in Special Issue
Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
 
 
Review
Peer-Review Record

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma

Cancers 2022, 14(19), 4616; https://doi.org/10.3390/cancers14194616
by Stefania De Lorenzo 1, Francesco Tovoli 2,3 and Franco Trevisani 2,4,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2022, 14(19), 4616; https://doi.org/10.3390/cancers14194616
Submission received: 11 September 2022 / Revised: 20 September 2022 / Accepted: 21 September 2022 / Published: 23 September 2022
(This article belongs to the Special Issue Targeted Treatment and Immunotherapy for Hepato-Biliary Tumors)

Round 1

Reviewer 1 Report

The manuscript is well-organized and well-written.

There are some minor comments.

HCCs are classified into eight histologic variants in 2019 WHO classification. It would be better to add the differences in resistance mechanisms to immune checkpoint inhibitors between histologic variants of HCC (e.g., conventional HCC vs. lymphocytes-rich HCC) or between underlying diseases (e.g., viral hepatitis B, alcoholic).

It would be better to check English spelling.

 e.g.,  subsequenty activated antigen-specific response -> subsequently  

          activated antigen-specific response

         heterogeneus antigen -> heterogeneous antigen

Author Response

The attached file contains our point-to-point response

Author Response File: Author Response.docx

Reviewer 2 Report


Comments for author File: Comments.pdf

Author Response

The attached file contains our point-to-point response. Thanks

Author Response File: Author Response.docx

Back to TopTop